Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press ReleasesSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

All Releases
View Summary Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results
Mar 13, 2015
PDF 93.9 KB Add to Briefcase
View Summary Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals' Analyst Day on Friday, March 13th
Mar 11, 2015
PDF 61.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
Mar 9, 2015
PDF 62.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in Several Solid Tumors, From Hanmi Pharmaceuticals
Mar 4, 2015
PDF 62.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 2015 RBC Capital Markets' Global Healthcare Conference on February 24th
Feb 20, 2015
PDF 59.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results and Analyst Day
Feb 17, 2015
PDF 61.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting
Feb 12, 2015
PDF 65.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
Dec 26, 2014
PDF 61.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, December 6-9, 2014
Dec 5, 2014
PDF 29.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare Conference on November 19th
Nov 12, 2014
PDF 12.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year
Nov 6, 2014
PDF 47.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference and Webcast
Oct 30, 2014
PDF 13.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs
Sep 18, 2014
PDF 26.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq™ (belinostat) for Injection with Patent Term Adjustment till 2027
Sep 16, 2014
PDF 59.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm. Co.
Sep 9, 2014
PDF 61.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Morgan Stanley Global Healthcare Conference in New York City on September 9th
Sep 2, 2014
PDF 58.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a Decision on a Potential Blockbuster
Aug 7, 2014
PDF 93.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Second Quarter 2014 Financial Results Teleconference and Webcast
Jul 31, 2014
PDF 59.9 KB Add to Briefcase
View Summary FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection
Jul 7, 2014
PDF 71.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd
May 30, 2014
PDF 58.5 KB Add to Briefcase
Showing 1-20 of 643 Page: 1 2 3 4 5 ... 33  Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPISpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Price:
6.01
Change:
+ 0.06
Day High:
6.05
Day Low:
5.88
Volume:
705,700
4:00 PM ET on Mar 27, 2015
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder ToolsSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Print Email

Search IRSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company